Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Nov 14;7(1):15506.
doi: 10.1038/s41598-017-15860-1.

Diagnostic performance of susceptibility-weighted magnetic resonance imaging for the detection of calcifications: A systematic review and meta-analysis

Affiliations
Meta-Analysis

Diagnostic performance of susceptibility-weighted magnetic resonance imaging for the detection of calcifications: A systematic review and meta-analysis

Lisa C Adams et al. Sci Rep. .

Abstract

Since its introduction, susceptibility-weighted-magnetic resonance imaging (SW-MRI) has shown the potential to overcome the insensitivity of MRI to calcification. Previous studies reporting the diagnostic performance of SW-MRI and magnetic resonance imaging (MRI) for the detection of calcifications are inconsistent and based on single-institution designs. To our knowledge, this is the first meta-analysis on SW-MRI, determining the potential of SW-MRI to detect calcifications. Two independent investigators searched MEDLINE, EMBASE and Web of Science for eligible diagnostic accuracy studies, which were published until March 24, 2017 and investigated the accuracy of SW-MRI to detect calcifications, using computed tomography (CT) as a reference. The QUADAS-2 tool was used to assess study quality and methods for analysis were based on PRISMA. A bivariate diagnostic random-effects model was applied to obtain pooled sensitivities and specificities. Out of the 4629 studies retrieved by systematic literature search, 12 clinical studies with 962 patients and a total of 1,032 calcifications were included. Pooled sensitivity was 86.5% (95%-confidence interval (CI): 73.6-93.7%) for SW-MRI and 36.7% (95%-CI:29.2-44.8%) for standard MRI. Pooled specificities of SW-MRI (90.8%; 95%-CI:81.0-95.8%) and standard MRI (94.2; 95%-CI:88.9-96.7%) were comparable. Results of the present meta-analysis suggest, that SW-MRI is a reliable method for detecting calcifications in soft tissues.

PubMed Disclaimer

Conflict of interest statement

LCA is participant in the BIH Charité - Junior Clinician Scientist Program funded by the Charité - Universitaetsmedizin Berlin and the Berlin Institute of Health. BH has received research grants for the Department of Radiology, Charité – Universitätsmedizin Berlin from the following companies: 1. Abbott, 2. Actelion Pharmaceuticals, 3. Bayer Schering Pharma, 4. Bayer Vital, 5. BRACCO Group, 6. Bristol-Myers Squibb, 7. Charite research organisation GmbH, 8. Deutsche Krebshilfe, 9. Dt. Stiftung für Herzforschung, 10. Essex Pharma, 11. EU Programmes, 12. Fibrex Medical Inc., 13. Focused Ultrasound Surgery Foundation, 14. Fraunhofer Gesellschaft, 15. Guerbet, 16. INC Research, 17. lnSightec Ud., 18. IPSEN Pharma, 19. Kendlel MorphoSys AG, 20. Lilly GmbH, 21. Lundbeck GmbH, 22. MeVis Medical Solutions AG, 23. Nexus Oncology, 24. Novartis, 25. Parexel Clinical Research Organisation Service, 26. Perceptive, 27. Pfizer GmbH, 28. Philipps, 29. Sanofis-Aventis S.A, 30. Siemens, 31. Spectranetics GmbH, 32. Terumo Medical Corporation, 33. TNS Healthcare GMbH, 34. Toshiba, 35. UCB Pharma, 36. Wyeth Pharma, 37. Zukunftsfond Berlin (TSB), 38. Amgen, 39. AO Foundation, 40. BARD, 41. BBraun, 42. Boehring Ingelheimer, 43. Brainsgate, 44. PPD (Clinical Research Organisation), 45. CELLACT Pharma, 46. Celgene, 47. CeloNova BioSciences, 48. Covance, 49. DC Deviees, Ine. USA, 50. Ganymed, 51. Gilead Sciences, 52. Glaxo Smith Kline, 53. ICON (Clinical Research Organisation), 54. Jansen, 55. LUX Bioseienees, 56. MedPass, 57. Merek, 58. Mologen, 59. Nuvisan, 60. Pluristem, 61. Quintiles, 62. Roehe, 63. Sehumaeher GmbH (Sponsoring eines Workshops), 64. Seattle Geneties, 65. Symphogen, 66. TauRx Therapeuties Ud., 67. Accovion, 68. AIO: Arbeitsgemeinschaft Internistische Onkologie, 69. ASR Advanced sleep research, 70. Astellas, 71. Theradex, 72. Galena Biopharma, 73. Chiltern, 74. PRAint, 75. lnspiremd, 76. Medronic, 77. Respicardia, 78. Silena Therapeutics, 79. Spectrum Pharmaceuticals, 80. St. Jude., 81. TEVA, 82. Theorem, 83. Abbvie, 84. Aesculap, 85. Biotronik, 86. Inventivhealth, 87. ISA Therapeutics, 88. LYSARC, 89. MSD, 90. novocure, 91. Ockham oncology, 92. Premier-research, 93. Psi-cro, 94. Tetec-ag, 94. Tetec-ag, 95. Winicker-norimed, 96. Achaogen Inc, 97. ADIR, 98. AstraZenaca AB, 99. Demira Inc, 100.Euroscreen S.A., 101. Galmed Research and Development Ltd., 102. GETNE, 103. Guidant Europe NV, 104. Holaira Inc., 105. Immunomedics Inc., 106. Innate Pharma, 107. Isis Pharmaceuticals Inc, 108. Kantar Health GmbH, 109. MedImmune Inc, 110. Medpace Germany GmbH (CRO), 111. Merrimack Pharmaceuticals Inc, 112. Millenium Pharmaceuticals Inc, 113. Orion Corporation Orion Pharma, 114. Pharmacyclics Inc, 115. PIQUR Therapeutics Ltd, 116. Pulmonx International Sárl, 117. Servier (CRO), 118. SGS Life Science Services (CRO), 119. Treshold Pharmaceuticals Inc. MRM has received grants from the Deutsche Forschungsgesellschaft (DFG) (MA 5943/31/41/91) and GIF (German Israel Research Foundation). The remaining authors have no conflicts of interest and did not receive any funds. There are no patents, products in development or marketed products to declare. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Figures

Figure 1
Figure 1
Study selection flowchart.
Figure 2
Figure 2
QUADAS-2 assessment of study quality. Grouped bar charts of the QUADAS-2 scores are expressed as percentage of the 12 included studies meeting each criterion. For each domain, the proportion of the included studies that indicate low/high/unclear concerns of applicability or risk of bias are displayed in light grey = “yes” answers (good quality), dark grey bar = “unclear” answers, and medium bar = “no” answers (low quality).
Figure 3
Figure 3
Forest plots showing the log diagnostic odds ratios (black squares) for susceptibility weighted imaging and standard magnetic resonance imaging (MRI) (where available) of each study with 95% confidence intervals (horizontal lines). The area of each square is proportional to the study’s weight in the meta-analysis and the summary measure of effect is plotted below as a diamond. An effect size of zero is indicated by the vertical dashed line.
Figure 4
Figure 4
Summary ROC curves of overall diagnostic accuracy for susceptibility weighted magnetic resonance imaging (SW-MRI) and magnetic resonance imaging (MRI) (A), for the overall diagnostic accuracy of SW-MRI (B) and the overall diagnostic accuracy of MRI (C). The false positive rate (1-specificity) is plotted against the false positive rate (1-specificity). The sROC curves show a deviation of the data points and especially for standard MRI, the extrapolation of the sROC curve is highly vulnerable to outliners.

References

    1. Bai, Y. et al. Susceptibility Weighted Imaging: A New Tool in the Diagnosis of Prostate Cancer and Detection of Prostatic Calcification. PLoS ONE8(1) (no pagination) (2013). - PMC - PubMed
    1. Zulfiqar M, Dumrongpisutikul N, Intrapiromkul J, Yousem DM. Detection of intratumoral calcification in oligodendrogliomas by susceptibility-weighted MR imaging. American Journal of Neuroradiology. 2012;33:858–864. doi: 10.3174/ajnr.A2862. - DOI - PMC - PubMed
    1. Odink AE, et al. Association between calcification in the coronary arteries, aortic arch and carotid arteries: the Rotterdam study. Atherosclerosis. 2007;193:408–413. doi: 10.1016/j.atherosclerosis.2006.07.007. - DOI - PubMed
    1. Wu Z, et al. Identification of calcification with MRI using susceptibility-weighted imaging: A case study. Journal of Magnetic Resonance Imaging. 2009;29:177–182. doi: 10.1002/jmri.21617. - DOI - PMC - PubMed
    1. Mittal S, Wu Z, Neelavalli J, Haacke EM. Susceptibility-weighted imaging: Technical aspects and clinical applications, part 2. American Journal of Neuroradiology. 2009;30:232–252. doi: 10.3174/ajnr.A1461. - DOI - PMC - PubMed

MeSH terms